The next chapter of radiopharmaceutical therapy starts now

Leading-edge technologies in the fight against cancer

We are a next generation radiopharmaceutical company, taking cancer head on.

For what’s ahead

Precision is the future of cancer care. Radiopharmaceutical products could offer new hope to patients with cancer.

What to expect

Treatments in development

We are pushing forward the next-generation of radiopharmaceuticals with our exciting pipeline.

About our Pipeline

Focused treatment

With focus and precision, our products direct the power of high energy particles towards cancer - and only cancer.

Learn the science

Clinical trials

Learn more about our ongoing study for Men with Metastatic Castration-Resistant Prostate Cancer. Now enrolling in phase 3.

Splash trial

News + Stories

Press Release
18 Aug
2022

POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial

In advance of the abstract publication, POINT hosted an educational webinar entitled “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”

Press Release
12 Aug
2022

POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights

Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release. PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha targeted program, enters Phase 1 clinical trial.